发布求助
文献互助 智能选刊 最新文献

Nephrology最新文献

筛选
英文 中文
Low dose glucocorticoids, mycophenolate mofetil and hydroxychloroquine in IgA nephropathy, an update of current clinical trials. 小剂量糖皮质激素、霉酚酸酯和羟氯喹治疗 IgA 肾病，当前临床试验的最新进展。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 Epub Date: 2024-07-18 DOI: 10.1111/nep.14369
Pei Chen, Jicheng Lv
{"title":"Low dose glucocorticoids, mycophenolate mofetil and hydroxychloroquine in IgA nephropathy, an update of current clinical trials.","authors":"Pei Chen, Jicheng Lv","doi":"10.1111/nep.14369","DOIUrl":"10.1111/nep.14369","url":null,"abstract":"<p><p>This mini-review explores glucocorticoids, mycophenolate mofetil (MMF), and hydroxychloroquine (HCQ) in IgA nephropathy (IgAN). It discusses conflicting findings from pivotal trials like TESTING and STOP-IgAN regarding glucocorticoid efficacy, emphasizing reduced-dose protocols as potentially safer options. MMF's effectiveness varies among populations, demonstrating promise in Chinese cohorts but yielding inconclusive results elsewhere. HCQ shows potential in reducing proteinuria, with ongoing trials investigating its long-term benefits.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"25-29"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mucosal targeting in IgA nephropathy targeting the gut associated lymphoid tissue. 针对肠道相关淋巴组织的 IgA 肾病粘膜靶向治疗。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14365
Jonathan Barratt
{"title":"Mucosal targeting in IgA nephropathy targeting the gut associated lymphoid tissue.","authors":"Jonathan Barratt","doi":"10.1111/nep.14365","DOIUrl":"10.1111/nep.14365","url":null,"abstract":"<p><p>IgA nephropathy is a mucosally driven disease and new therapeutic approaches are specifically targeting the mucosal production of IgA in the hope that this will lead to a reduction in circulating IgA immune complexes and mesangial IgA deposition. In this lecture, I discuss the rationale for targeting the mucosal immune system of the gut and the existing data from clinical trials supporting such an approach as a disease modifying treatment for IgA nephropathy.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"34-36"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IgA nephropathy 'Treatment to Prevention'. 从治疗到预防 "的 IgA 肾病。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14299
Yusuke Suzuki
{"title":"IgA nephropathy 'Treatment to Prevention'.","authors":"Yusuke Suzuki","doi":"10.1111/nep.14299","DOIUrl":"https://doi.org/10.1111/nep.14299","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"47-50"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rhodojaponin VI ameliorates podocyte injury related with MDM2/Notch1 pathway in rat experimental membranous nephropathy. 红豆皂苷 VI 可改善大鼠实验性膜性肾病中与 MDM2/Notch1 通路相关的荚膜细胞损伤。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1111/nep.14337
Anni Song, Ruiwei Yan, Yue Qiu, Xingjie Yin, Jing Xiong, Guangmin Yao, Chun Zhang
{"title":"Rhodojaponin VI ameliorates podocyte injury related with MDM2/Notch1 pathway in rat experimental membranous nephropathy.","authors":"Anni Song, Ruiwei Yan, Yue Qiu, Xingjie Yin, Jing Xiong, Guangmin Yao, Chun Zhang","doi":"10.1111/nep.14337","DOIUrl":"10.1111/nep.14337","url":null,"abstract":"<p><strong>Aim: </strong>Rhodojaponin VI (R-VI) is the key compound of Rhododendron molle G. Don (Ericaceae) (RM) with effective clinical application in rheumatoid arthritis and chronic glomerulonephritis. In our study, we tried to explore the effect of R-VI on the rat model of membranous nephropathy.</p><p><strong>Methods: </strong>The rat model of passive heymann nephritis (PHN) was established by injecting sheep anti-rat Fx1A serum at a single dose through the tail. The rats were orally administered R-VI (0.02 mg/kg) or FK506 (1 mg/kg) 1 day before PHN induction, which was kept for 4 weeks. Urine and blood samples as well as kidney tissue were collected for analysis. C5b-9-induced human podocyte cell (HPC) was employed for experiments in vitro.</p><p><strong>Results: </strong>R-VI could alleviate glomerulonephritis progression and podocyte injury in PHN rats, as indicated by the decreased proteinuria and the elevated level of albumin, accompanied with reduced immune deposits, reversed podocyte injury in the kidneys. Furthermore, R-VI suppressed murine double minute 2 (MDM2) expression without the alteration in the protein level of p53 and decreased Notch1 expression independent of Numb regulation. Pre-treatment with R-VI in C5b-9-induced HPC blocked MDM2/Notch1 signalling pathway.</p><p><strong>Conclusion: </strong>Thus, R-VI ameliorates podocyte injury in rats with PHN, which was probably related with MDM2/Notch1 signalling pathway.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"555-564"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glomerular basement membrane ultrastructural changes in a patient with COQ2 glomerulopathy: A case report. 一名 COQ2 肾小球病变患者的肾小球基底膜超微结构变化：病例报告。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 Epub Date: 2024-06-04 DOI: 10.1111/nep.14329
Liuyu Sun, Yali Ren, Baige Su, Suxia Wang, Xuhui Zhong, Yuwu Jiang, Fang Wang
{"title":"Glomerular basement membrane ultrastructural changes in a patient with COQ2 glomerulopathy: A case report.","authors":"Liuyu Sun, Yali Ren, Baige Su, Suxia Wang, Xuhui Zhong, Yuwu Jiang, Fang Wang","doi":"10.1111/nep.14329","DOIUrl":"10.1111/nep.14329","url":null,"abstract":"<p><p>Primary coenzyme Q10 deficiency-1, caused by COQ2 disease-causing variants, is an autosomal recessive disorder, and genetic testing is the gold standard for diagnosing this condition. A Chinese boy with steroid-resistant nephrotic syndrome, focal segmental glomerulosclerosis, and progressive kidney insufficiency was included in the study. Electron microscopy revealed the glomerular basement membrane with irregular thickness and lamellation with diffuse effacement of foot processes in the podocytes, and swollen mitochondria with abnormal cristae in the podocytes. Coenzyme Q10 supplementation started about 3 weeks after the onset of mild kidney dysfunction did not improve the proband's kidney outcome. Proband-only whole-exome sequencing and Sanger sequencing revealed two heteroallelic COQ2 variants: a maternally inherited novel variant c.1013G > A[p.(Gly338Glu)] in exon 6 and a variant of unknown origin c.1159C > T[p.(Arg387*)] in exon 7. Subsequent long-read sequencing demonstrated these two variants were located on different alleles. Our report extends the phenotypic and genotypic spectrum of COQ2 glomerulopathy.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"612-616"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141262442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathology of IgA nephropathy: A global perspective. IgA 肾病的病理学：全球视角。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14343
Ian S D Roberts
{"title":"Pathology of IgA nephropathy: A global perspective.","authors":"Ian S D Roberts","doi":"10.1111/nep.14343","DOIUrl":"https://doi.org/10.1111/nep.14343","url":null,"abstract":"<p><p>Worldwide adoption of the Oxford Classification of IgA nephropathy (IgAN) has enabled comparison of pathology data from clinicopathological studies in different regions of the world. It is apparent that the frequency of Oxford Classification MEST-C scores shows geographic variations. These in part reflect differences in the stage of disease at diagnosis, criteria for performing biopsies and inclusion in clinical studies, and pathologist reporting practice. However, there appears to be a true geographic difference in the frequency of glomerular inflammation and crescents with a 2-3 fold greater proportion of patients showing these changes in East Asia when compared to Europe and North America. This indicates that the pathology of IgAN is influenced by genetic background. Geographic differences in the pathology of IgAN might underly the reported differences in clinical presentation and outcome in different regions of the world, and has important implications for clinical trials and patient management.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"71-74"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of endothelin receptor antagonists in IgA nephropathy. 内皮素受体拮抗剂在 IgA 肾病中的作用。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14364
Mitchell Hunter-Dickson, Muh Geot Wong
{"title":"The role of endothelin receptor antagonists in IgA nephropathy.","authors":"Mitchell Hunter-Dickson, Muh Geot Wong","doi":"10.1111/nep.14364","DOIUrl":"https://doi.org/10.1111/nep.14364","url":null,"abstract":"<p><p>There is growing evidence of endothelin receptor antagonists (ERAs) in renoprotection in proteinuric kidney disease including IgA nephropathy (IgAN). Here, we review current evidence, including the use of sparsentan, atrasentan and zibotentan in IgAN. Recent trails of combination therapy including SGLT2 inhibitors and ERAs suggest possible benefit in further reduction of proteinuria and reducing ERA fluid-retention side effects although more evidence is needed for clinical applications.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"30-33"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilizing complement inhibition in IgA nephropathy. 利用补体抑制治疗 IgA 肾病。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-09-01 DOI: 10.1111/nep.14347
Richard Lafayette
{"title":"Utilizing complement inhibition in IgA nephropathy.","authors":"Richard Lafayette","doi":"10.1111/nep.14347","DOIUrl":"10.1111/nep.14347","url":null,"abstract":"<p><p>The role of complement in the pathogenesis of IgA nephropathy has been heavily explored over the past 50 years. This has led to the general acceptance that complement plays an important role in the clinical presentation and risk for progression of disease in patients with IgA nephropathy. Herein, we review the evidence for complement activation in IgA nephropathy, focusing on evidence that the lectin and alternate pathways are the main actors. We are entering an era of intense investigation of various inhibitors of complement, which should ultimately be the best indicator of contributions of the lectin, alternate and common complement pathways to disease burden. More importantly, we will see if these efforts result in the discovery of clinically relevant options in managing this important disease.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 2 ","pages":"44-46"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
59th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), 31 August-4 September 2024. 澳大利亚和新西兰肾脏病学会（ANZSN）第 59 届科学年会，2024 年 8 月 31 日至 9 月 4 日。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-08-01 DOI: 10.1111/nep.14360
{"title":"59th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), 31 August-4 September 2024.","authors":"","doi":"10.1111/nep.14360","DOIUrl":"https://doi.org/10.1111/nep.14360","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 1 ","pages":"10-23"},"PeriodicalIF":2.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
59th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), 31 August-4 September 2024. 澳大利亚和新西兰肾脏病学会（ANZSN）第 59 届科学年会，2024 年 8 月 31 日至 9 月 4 日。
IF 2.4 4区 医学
Nephrology Pub Date : 2024-08-01 DOI: 10.1111/nep.14355
{"title":"59th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), 31 August-4 September 2024.","authors":"","doi":"10.1111/nep.14355","DOIUrl":"https://doi.org/10.1111/nep.14355","url":null,"abstract":"","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":"29 Suppl 1 ","pages":"5"},"PeriodicalIF":2.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信